He conducted his postdoctoral research at Brigham and Womens Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. Kathryn's primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Peter Kolchinsky, RA Capital's founder and managing partner. His graduate research investigated innate immune responses after intracerebral hemorrhage. He was named an MIT Technology Review 100 innovators under 35 for his MIT Media Lab social enterprise, Dimagi, that has impacted millions with its mobile data collection platform. After his stay at IncTank Ventures, he joined Schrdingers Drug Discovery Application Group and through various roles ascended to a Research Leader within the organization. Brians primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. in Neuroscience from University of Pennsylvania and a PhD in Neuroscience from University of Oxford. This ground-breaking new book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines (January 20, 2020), by Peter Kolchinsky, PhD, examines the healthcare landscape through the lens of the biotech social contract with America - the implicit agreement between the biopharmaceutical industry and American society - including the government's role in inventing . Many of the assets he contributed to within HNDC have been out-licensed to various Cambridge and Boston-based startups and biotech firms for further development. Peter Kolchinsky Age : 46 Linked companies : ARS Pharmaceuticals, Inc. - Research Alliance Corp. II - Wave Life Sciences Ltd. - Icosavax, Inc. Summary Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. In 2013 was awarded a Medical Research Council Clinical Scientist Fellowship. Dan holds a BS with Honors in Biology from Yale University and a PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences. Cristinas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prithviraj Singha Roy is a Senior Associate on the Investment Team at RA Capital Management. Prior to RA, Henry gained experience as an Investment Banking Analyst at SVB Leerink. His primary responsibilities are to advise RA Capital on private investments, coordinate with portfolio companies regarding deal structures and terms, and counsel RA Ventures on new company formation. Before joining Proteon, Tim was the COO of Trine Pharmaceuticals and he held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. Nate Davis is an Analyst on the Investment Team at RA Capital Management. He holds a BA in Environmental Engineering from Dartmouth College (1998), an MA in International Finance and Energy Policy from John Hopkins University (2008), an MS in Materials Science from Columbia University (2012), and a Masters of Strategic Studies from the Army War College (2020). Kates primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Dan studied Network Communications & Information Services at Lincoln Technical. The Kolchinskys came to the United States from Russia in 1981, when Peter was 4. Elena Forchielli is an Associate within the Planetary Health division of RA Capital Management. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Prior to GHP, Lorena served as an Assurance Senior at EY. Benjamins primary responsibilities at RA Capital are to coordinate various projects across the Venture Team and oversee their initiation, planning, and execution. Ross Chikarmane is an Associate with the TechAtlas division of RA Capital Management. Mario has more than two decades of experience in vaccinology, virology and immunology in large pharma, government, academy, and biotech settings. Benjamin Hicks is a Venture Operations Associate at RA Capital Management. Kathryns primary responsibility at RA is to invest in companies developing solutions that address climate change and environmental sustainability. Jeff Breay is a Head Trader at RA Capital Management. Brian holds a BA in Politics from Princeton University and an MBA in Health Care Management from University of Pennsylvania. Jenna Hebert is an Associate within the TechAtlas division of RA Capital Management. Peter Kolchinsky founded 5 companies, among them: Research Alliance Corp. II, Therapeutics Acquisition Corp. and RA Capital Management LP (Private Equity). Mario is a Venture Partner and Head of Vaccines at RA Capital. She works with RAs newcos to develop optimal pitch decks and public messaging, authors articles, and runs the firms internal and external business courses. He holds a BA in History from University of Massachusetts, Amherst and a Master's of Urban Affairs from Boston University. He was previously a marketing manager at Brighton House Associates, assisting with fundraising campaigns for a diverse group of investment managers, including private equity, venture capital, real estate, and hedge funds. She is a CPA. Receptionist and Facilities Administrator. Jesse earned his Ph.D. in Biological Chemistry from MIT and was a Harvard Origins Research Fellow. In this role, he gained broad expertise across all phases of drug discovery, early development, and clinical research. Toms primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior RA, Cony was Executive Vice President and Chief Business Officer at Schrdinger for eight years, responsible for business development involving strategic collaborations and new company formation as well as software sales in the US and Japan. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Dr. Kolchinsky is a founding Partner and Portfolio Manager at RA Capital. Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. Prior to joining RAVen, Michael was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. She holds a BS in Finance from Elon University and an MBA from Babson College. Anas previous experience includes Research Assistant positions at Massachusetts Eye and Ear Hospital, the Lupus Clinic/Renal Department at the BU Medical Center, and Harvard University Department of Molecular and Cellular Biology. Prior to Bernstein, Joey held a Consultant role at FactSet. Prior to these companies, James held senior research leadership roles in the gene and stem cell therapy companies Cell Genesys, Phylogix, and Somatix Therapy. Joshs primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Bretts primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Chriss primary responsibility at RA Capital is to cover the biotech and pharma industry. Previously, Daniel spent time working at ARPA-E and the Center for Climate and Energy Solutions, and has published research examining potential early markets for fusion energy as well as techno-economic synergies between direct air capture and advanced nuclear. Prior to RA, she served as Researcher and Collaborator at New Care, a startup focused on improving access to early childcare for lower income families. She holds a BBA in Marketing from Loyola University Maryland. Anurag Kondapalli is a Principal on the Investment Team at RA Capital Management. Christy is a Senior Associate with the TechAtlas division of RA Capital Management. After the acquisition, Tim was named President of Genzymes Renal Division and GelTex Pharmaceuticals. From 1990- 1997, he held investment, business development, R&D, and marketing positions at DuPont Ventures. Peter Kolchinsky, Ph.D. Board Member Peter Kolchinsky, Ph.D., has more than 18 years of experience in healthcare investing and is the founder of and a managing partner at RA Capital. Joeys primary responsibility is to manage workflows for investor transaction processing and investor reporting in collaboration with the fund's administrator. Before her time at New Care, she was a Student Researcher at Boston Childrens Hospital Labs of Cognitive Neuroscience. Mario held a Project Director position at BARDA working on Universal Flu Vaccine and leading the technical selection and completion of multiyear/multi million vaccine development programs. She is a Clinical Reader at Kings College London with a laboratory working on translational adaptions to CAR T cell engineering to optimize clinical utility. Tom has a BS in Physiological Sciences from University of California Los Angeles. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners within RAVen. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Tim began his career at Merck & Co., serving in multiple commercial roles in its cardiovascular, gastrointestinal, and managed care divisions. Her doctoral research investigated the folding and aggregation of gamma-crystallins associated with cataract formation. Lorena has dual degrees from Beijing Foreign Studies University: a Bachelor of Business Administration in Accounting and a Bachelor of Arts in English Literature. Nandita has also held strategic and group head roles in the Novartis Preclinical Investigative Toxicology organization. He also holds a B.A. Most recently, he was Chief Technology Officer at Vor Bio where he built the technical operations team responsible for process development, analytical development, supply chain and manufacturing support of a CRISPR gene-edited HSPC product and oversaw the companys CAR-T efforts. Ben has also mapped competitive landscapes with a focus on cardiovascular diseases and regenerative medicine as a member of the Cardio-Renal Team within the TechAtlas division of RA Capital.
1969 Firebird 6 Cylinder For Sale, Google Incognito Lawsuit Claim Form, Articles P